ACIU
AC Immune Ltd
2.60$
-0.8%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Cash Flow
All figures in millions of CHF.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.5 | -6.9 | -12 | -9.0 | -7.5 | 6.4 | -13 | -7.1 | -12 | -12 | 66 | -15 | 17 | -13 | -9.7 | -15 | -16 | -19 | -17 | -16 | -14 | -18 | -23 | -19 | -14 | -17 | -17 | -14 | -13 | -16 | 1.0 | 73 | -14 | 5.9 | -19 | -16 | -18 | -16 | – | – | – | |
| 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 | 0.5 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.7 | – | – | – | |
| 0.2 | 1.0 | 0.1 | 0.2 | 0.6 | 0.8 | 0.6 | 0.7 | 0.6 | 0.6 | 0.6 | 0.6 | 0.9 | 0.8 | 0.9 | 1.0 | 1.2 | 1.0 | 0.9 | 0.8 | 1.4 | 1.0 | 1.0 | 0.9 | 0.6 | 0.9 | 1.5 | 0.6 | 0.3 | 0.8 | 1.9 | 0.6 | 1.2 | 1.0 | 1.6 | 1.1 | 0.8 | 0.9 | – | 2.6 | – | |
| – | -1.9 | 1.8 | 4.3 | -0.2 | 6.1 | 1.0 | 0.4 | 2.1 | 0.7 | -2.5 | 2.8 | 0.8 | 1.4 | 1.5 | 1.0 | 1.5 | 1.0 | 0.4 | 1.3 | -3.0 | -0.6 | 1.0 | 0.5 | 0.6 | 1.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 16 | 1.1 | -4.3 | -1.1 | 1.4 | 2.0 | -2.8 | 3.2 | -0.6 | 2.0 | 4.6 | -1.3 | -2.4 | 4.8 | -4.0 | -0.6 | 2.1 | -1.4 | -1.5 | 1.5 | 3.8 | 1.0 | -5.9 | -0.9 | -1.2 | 0.2 | -1.5 | 0.2 | 0.4 | -15 | 18 | 91 | -24 | 22 | -2.3 | 1.5 | -0.1 | -3.8 | – | – | – | |
| 0.3 | 0.3 | 0.6 | 0.9 | 0.3 | 0.0 | 1.1 | 0.4 | 0.1 | 0.2 | 0.5 | 0.3 | 0.5 | 0.6 | 0.2 | 0.4 | 0.3 | 0.9 | 0.8 | 0.6 | 0.5 | 0.7 | 0.5 | 0.5 | 0.1 | 0.0 | 0.2 | 0.2 | 0.3 | 0.2 | 0.2 | 0.1 | 0.2 | 0.1 | 0.4 | 0.4 | 0.1 | 0.1 | 0.0 | 0.0 | 0.2 | |
| -0.3 | -0.3 | -0.6 | -0.9 | -0.3 | 0.0 | -1.2 | -0.4 | -0.1 | -30 | -51 | -0.3 | -10 | -5.6 | -0.2 | 9.6 | 15 | 4.2 | -0.8 | -31 | -0.5 | -22 | -0.5 | 24 | -5.1 | 5.0 | 43 | -5.2 | 4.7 | 23 | -24 | -76 | -2.1 | -3.8 | 3.0 | 24 | 21 | 16 | – | – | – | |
| – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 69 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 112 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | -0.1 | 0.0 | 0.0 | – | 0.0 | – | – | – | – | 0.0 | 0.0 | – | – | – | – | – | – | 0.0 | – | – | – | – | – | – | |
| – | 0.2 | 0.1 | 0.1 | 0.0 | 0.2 | 0.2 | 0.1 | -0.3 | -0.3 | 50 | 0.0 | -0.1 | 0.0 | -0.4 | -0.1 | -0.1 | -0.4 | -0.1 | -0.1 | -0.1 | 23 | -0.1 | -0.1 | -0.1 | -0.1 | – | – | – | – | – | – | -0.2 | -0.2 | -0.3 | -0.3 | -0.3 | -0.3 | – | – | – | |
| 68 | -2.5 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 110 | -0.5 | 50 | -0.5 | -0.1 | 0.0 | -0.4 | -0.1 | 0.1 | -0.5 | 7.7 | 0.0 | 4.3 | 29 | -0.9 | -0.1 | -0.1 | -0.2 | -0.1 | 1.9 | 0.4 | 41 | -0.7 | -0.1 | -0.2 | -0.2 | -0.3 | -0.2 | -0.3 | -0.3 | – | – | – | |
| 75 | -5.4 | -14 | -14 | -7.0 | 7.2 | -15 | -7.0 | 96 | -43 | 66 | -16 | 6.7 | -19 | -11 | -5.4 | -0.9 | -16 | -9.8 | -47 | -11 | -11 | -24 | 5.3 | -19 | -13 | 26 | -17 | -8.1 | 47 | -21 | -5.4 | -19 | 3.9 | -16 | 5.8 | 2.0 | -0.8 | -10.0 | – | – | |
| 8.2 | -7.2 | -12 | -10.0 | -7.8 | 6.4 | -14 | -7.5 | -12 | -12 | 65 | -15 | 17 | -13 | -9.9 | -15 | -16 | -20 | -18 | -17 | -15 | -19 | -24 | -20 | -14 | -17 | -17 | -14 | -14 | -16 | 0.8 | 73 | -14 | 5.8 | -19 | -16 | -18 | -17 | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.